BCRX BioCryst Pharmaceuticals, Inc.
Healthcare$8.47+2.17%ClosedMarket Cap: $1.78B
As of 2026-05-26
Valuation
P/E (TTM)
7.60
PEG
0.02
P/B
-3.63
P/S
1.96
EV/EBITDA
-6.47
DCF Value
$-133.55
FCF Yield
16.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
18.9%
Operating Margin
-43.1%
Net Margin
-51.7%
ROE
123.6%
ROA
-98.5%
ROIC
-122.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $156.4M | -349.5% | $-701.6M | $-721.8M | $— | — |
| Q4 null | $406.6M | 97.6% | $260.4M | $245.8M | $— | — |
| FY null | $874.8M | 97.8% | $341.0M | $263.9M | $— | — |
| Q3 null | $159.4M | 98.4% | $29.6M | $12.9M | $— | — |
| Q2 null | $163.4M | 98.3% | $29.8M | $5.1M | $— | — |
| Q1 null | $145.5M | 96.9% | $21.2M | $32.0K | $— | — |
| Q4 null | $131.5M | 95.3% | $-4.5M | $-26.8M | $— | — |
| FY null | $450.7M | 97.2% | $-2.5M | $-88.9M | $— | — |
| Q3 null | $117.1M | 97.2% | $7.7M | $-14.0M | $— | — |
| Q2 null | $109.3M | 98.4% | $8.8M | $-12.7M | $— | — |
| Q1 null | $92.8M | 98.6% | $-14.5M | $-35.4M | $— | — |
| Q4 2023 | $93.4M | 98.2% | $-42.7M | $-61.7M | $-0.31 | — |